Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: Pre-market Movers » 09:24
06/09/20
06/09
09:24
06/09/20
09:24
M

Macy's

$9.57 /

+0.8 (+9.12%)

, TIF

Tiffany

$122.20 /

+0.26 (+0.21%)

, SIG

Signet Jewelers

$16.90 /

+1.845 (+12.26%)

, LOVE

Lovesac

$19.72 /

+1.92 (+10.79%)

, AMPH

Amphastar

$20.09 /

+0.57 (+2.92%)

, IMUX

Immunic

$13.77 /

+0.83 (+6.41%)

, SLNO

Soleno Therapeutics

$3.25 /

-0.04 (-1.22%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
TIF Tiffany
$122.20 /

+0.26 (+0.21%)

SLNO Soleno Therapeutics
$3.25 /

-0.04 (-1.22%)

SIG Signet Jewelers
$16.90 /

+1.845 (+12.26%)

M Macy's
$9.57 /

+0.8 (+9.12%)

LOVE Lovesac
$19.72 /

+1.92 (+10.79%)

IMUX Immunic
$13.77 /

+0.83 (+6.41%)

AMPH Amphastar
$20.09 /

+0.57 (+2.92%)

M Macy's
$9.57 /

+0.8 (+9.12%)

05/22/20 Deutsche Bank
Macy's price target lowered to $5 from $7 at Deutsche Bank
05/07/20 Deutsche Bank
Macy's price target lowered to $7 from $20 at Deutsche Bank
05/04/20 Cleveland Research
Cleveland Research sees further risk to Macy's second half comps
05/01/20 OTR Global
Macy's downgraded to Negative from Mixed at OTR Global
TIF Tiffany
$122.20 /

+0.26 (+0.21%)

06/05/20 Societe Generale
SocGen backs Buy on LVMH after Tiffany statement
06/05/20 Societe Generale
Societe Generale still sees LVMH going through with deal for Tiffany
06/03/20 Credit Suisse
Tiffany could be worth $60-$75 if LVMH puts 'deal on ice,' says Credit Suisse
12/09/19 Cowen
Tiffany downgraded to Market Perform from Outperform at Cowen
SIG Signet Jewelers
$16.90 /

+1.845 (+12.26%)

06/03/20 Northcoast
Signet Jewelers sales and EPS estimates raised at Northcoast
03/27/20 BofA
Signet Jewelers downgraded to Underperform from Neutral at BofA
03/27/20 BofA
Signet Jewelers downgraded to Underperform from Neutral at BofA
01/17/20 Citi
Signet Jewelers price target raised to $22 from $13 at Citi
LOVE Lovesac
$19.72 /

+1.92 (+10.79%)

06/02/20 Craig-Hallum
Lovesac price target raised to $26 from $15 at Craig-Hallum
05/04/20 Canaccord
Lovesac omnichannel allows for growth during pandemic, says Canaccord
04/28/20 BTIG
Lovesac initiated with a Buy at BTIG
04/17/20
Fly Intel: Top five analyst upgrades
AMPH Amphastar
$20.09 /

+0.57 (+2.92%)

05/01/20
Fly Intel: Top five analyst initiations
05/01/20 Northland
Amphastar initiated with an Outperform at Northland
01/22/20 Wells Fargo
Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo
07/10/19 Wells Fargo
Amneal news reflects challenges in generics industry, says Wells Fargo
IMUX Immunic
$13.77 /

+0.83 (+6.41%)

06/04/20 Wedbush
Wedbush starts Immunic at Outperform with $59 price target
06/04/20 Wedbush
Immunic initiated with an Outperform at Wedbush
05/11/20
Fly Intel: Top five analyst initiations
05/11/20 H.C. Wainwright
Immunic initiated with a Buy, $45 price target at H.C. Wainwright
SLNO Soleno Therapeutics
$3.25 /

-0.04 (-1.22%)

04/07/20 Craig-Hallum
Millendo failure in PWS doesn't add risk to Soleno readout, says Craig-Hallum
01/10/20 Craig-Hallum
Soleno Therapeutics initiated with a Buy, $8 price target at Craig-Hallum
01/10/20 Craig-Hallum
Soleno Therapeutics initiated with a Buy at Craig-Hallum
12/23/19 Laidlaw
Soleno Therapeutics resumed with a Buy at Laidlaw
TIF Tiffany
$122.20 /

+0.26 (+0.21%)

SLNO Soleno Therapeutics
$3.25 /

-0.04 (-1.22%)

SIG Signet Jewelers
$16.90 /

+1.845 (+12.26%)

M Macy's
$9.57 /

+0.8 (+9.12%)

LOVE Lovesac
$19.72 /

+1.92 (+10.79%)

IMUX Immunic
$13.77 /

+0.83 (+6.41%)

AMPH Amphastar
$20.09 /

+0.57 (+2.92%)

TIF Tiffany
$122.20 /

+0.26 (+0.21%)

M Macy's
$9.57 /

+0.8 (+9.12%)

AMPH Amphastar
$20.09 /

+0.57 (+2.92%)

TIF Tiffany
$122.20 /

+0.26 (+0.21%)

SIG Signet Jewelers
$16.90 /

+1.845 (+12.26%)

M Macy's
$9.57 /

+0.8 (+9.12%)

LOVE Lovesac
$19.72 /

+1.92 (+10.79%)

IMUX Immunic
$13.77 /

+0.83 (+6.41%)

TIF Tiffany
$122.20 /

+0.26 (+0.21%)

SLNO Soleno Therapeutics
$3.25 /

-0.04 (-1.22%)

SIG Signet Jewelers
$16.90 /

+1.845 (+12.26%)

M Macy's
$9.57 /

+0.8 (+9.12%)

Hot Stocks
Amphastar receives FDA approval for Succinylcholine Chloride Injection » 06:06
06/09/20
06/09
06:06
06/09/20
06:06
AMPH

Amphastar

$20.09 /

+0.57 (+2.92%)

, PFE

Pfizer

$36.59 /

+0.62 (+1.72%)

Amphastar Pharmaceuticals…

Amphastar Pharmaceuticals (AMPH) announces that the U.S. FDA has approved its Abbreviated New Drug Application for Succinylcholine Chloride Injection USP, 200 mg/10 mL Multiple-Dose Vial. Amphastar's newly approved drug product was determined by the FDA to be therapeutically equivalent to Quelicin Multiple-Dose Vial) distributed in the United States by Pfizer (PFE). Succinylcholine Chloride Injection is for intramuscular and intravenous use. It is indicated as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

ShowHide Related Items >><<
PFE Pfizer
$36.59 /

+0.62 (+1.72%)

AMPH Amphastar
$20.09 /

+0.57 (+2.92%)

AMPH Amphastar
$20.09 /

+0.57 (+2.92%)

05/01/20
Fly Intel: Top five analyst initiations
05/01/20 Northland
Amphastar initiated with an Outperform at Northland
01/22/20 Wells Fargo
Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo
07/10/19 Wells Fargo
Amneal news reflects challenges in generics industry, says Wells Fargo
PFE Pfizer
$36.59 /

+0.62 (+1.72%)

06/08/20 Piper Sandler
Opko Health, Pfizer data show IGF-1 normal at ENDO, says Piper Sandler
06/01/20 Morgan Stanley
Lilly trial has higher risk and reward after Pfizer failure, says Morgan Stanley
06/01/20 Barclays
Pfizer price target lowered to $35 from $37 at Barclays
05/21/20 Piper Sandler
Gilead's filgotinib likely being underestimated by Street, says Piper Sandler
PFE Pfizer
$36.59 /

+0.62 (+1.72%)

AMPH Amphastar
$20.09 /

+0.57 (+2.92%)

PFE Pfizer
$36.59 /

+0.62 (+1.72%)

AMPH Amphastar
$20.09 /

+0.57 (+2.92%)

PFE Pfizer
$36.59 /

+0.62 (+1.72%)

PFE Pfizer
$36.59 /

+0.62 (+1.72%)

Over a month ago
Earnings
Amphastar reports Q1 adj. EPS 17c, consensus 8c » 16:30
05/07/20
05/07
16:30
05/07/20
16:30
AMPH

Amphastar

$17.57 /

+0.25 (+1.44%)

Reports Q1 revenue…

Reports Q1 revenue $84.69M, consensus $82.83M. Jack Zhang, Amphastar's president and CEO, commented: "The first quarter of 2020 was very strong for Amphastar, as we had strong sales from Primatene(R) Mist and from our hospital products, including sales of Sodium Bicarbonate, which we filled in our newly approved finished product facility in South El Monte, California."

ShowHide Related Items >><<
AMPH Amphastar
$17.57 /

+0.25 (+1.44%)

05/01/20
Fly Intel: Top five analyst initiations
05/01/20 Northland
Amphastar initiated with an Outperform at Northland
01/22/20 Wells Fargo
Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo
07/10/19 Wells Fargo
Amneal news reflects challenges in generics industry, says Wells Fargo
Initiation
Fly Intel: Top five analyst initiations » 10:09
05/01/20
05/01
10:09
05/01/20
10:09
YMAB

Y-mAbs Therapeutics

$32.79 /

-0.9 (-2.67%)

, LYFT

Lyft

$30.80 /

-2.085 (-6.34%)

, FGEN

FibroGen

$35.43 /

-1.43 (-3.88%)

, LUMO

Lumos Pharma

$9.50 /

+ (+0.00%)

, AMPH

Amphastar

$16.76 /

-0.17 (-1.00%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Y-mAbs Therapeutics (YMAB) initiated with a Buy at Janney Montgomery Scott. 2. Lyft (LYFT) coverage resumed with a Buy at Citi. 3. FibroGen (FGEN) initiated with a Market Perform at Cowen. 4. Lumos Pharma (LUMO) initiated with a Buy at Roth Capital. 5. Amphastar (AMPH) initiated with an Outperform at Northland. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
YMAB Y-mAbs Therapeutics
$32.79 /

-0.9 (-2.67%)

05/01/20 Janney Montgomery Scott
Y-mAbs Therapeutics initiated with a Buy at Janney Montgomery Scott
04/29/20 Morgan Stanley
Y-mAbs Therapeutics initiated with an Equal Weight at Morgan Stanley
12/24/19 JPMorgan
Y-mAbs Therapeutics initiated with an Overweight at JPMorgan
11/20/19 Guggenheim
Guggenheim starts 'underappreciated' Y-mAbs Therapeutics at Buy
LYFT Lyft
$30.80 /

-2.085 (-6.34%)

05/01/20 Citi
Lyft coverage resumed with a Buy at Citi
04/28/20 Needham
Lyft price target lowered to $41 from $48 at Needham
04/21/20
Fly Intel: Top five analyst initiations
04/21/20 Guggenheim
Guggenheim raises two auto parts retailers, cuts one supplier in sector shake-up
FGEN FibroGen
$35.43 /

-1.43 (-3.88%)

05/01/20 Cowen
FibroGen initiated with a Market Perform at Cowen
04/27/20
Fly Intel: Top five analyst initiations
04/27/20 BofA
FibroGen initiated with a Neutral at BofA
04/27/20 BofA
FibroGen initiated with a Neutral at BofA
LUMO Lumos Pharma
$9.50 /

+ (+0.00%)

05/01/20 Roth Capital
Lumos Pharma initiated with a Buy at Roth Capital
04/16/20 Jefferies
Lumos Pharma initiated with a Buy at Jefferies
AMPH Amphastar
$16.76 /

-0.17 (-1.00%)

05/01/20 Northland
Amphastar initiated with an Outperform at Northland
01/22/20 Wells Fargo
Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo
07/10/19 Wells Fargo
Amneal news reflects challenges in generics industry, says Wells Fargo
06/06/19 Wells Fargo
Wells says filings indicate resolution of Amphastar dispute with Sandoz/Momenta
Initiation
Amphastar initiated with an Outperform at Northland » 08:33
05/01/20
05/01
08:33
05/01/20
08:33
AMPH

Amphastar

$16.93 /

-0.61 (-3.48%)

Northland analyst Tim…

Northland analyst Tim Chiang initiated coverage of Amphastar Pharmaceuticals with an Outperform rating and $23 price target. The analyst believes the "steady ramp" of Primatene Mist sales in the U.S., along with additional potential approvals and launches within its Amphastar's generic drug pipeline, are potential catalysts for the shares. He points out that Primatene Mist is the only FDA approved over-the-counter inhaler for relief of intermittent asthma symptoms. Further, the company's pipeline includes more than 20 product candidates in the area of generics, biosimilars, and proprietary products, Chiang tells investors in a research note.

ShowHide Related Items >><<
AMPH Amphastar
$16.93 /

-0.61 (-3.48%)

01/22/20 Wells Fargo
Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo
07/10/19 Wells Fargo
Amneal news reflects challenges in generics industry, says Wells Fargo
06/06/19 Wells Fargo
Wells says filings indicate resolution of Amphastar dispute with Sandoz/Momenta
05/30/19 Wells Fargo
U.S. generic data continues to show challenging environment, says Wells Fargo
Hot Stocks
Amphastar granted ANDA for Epinephrine Injection by FDA » 06:03
04/27/20
04/27
06:03
04/27/20
06:03
AMPH

Amphastar

$16.75 /

+0.23 (+1.39%)

Amphastar Pharmaceuticals…

Amphastar Pharmaceuticals announces that the FDA has granted approval of its Abbreviated New Drug Application, or ANDA, for Epinephrine Injection, USP 30mg/30mL Multiple Dose Vial. Amphastar's newly approved drug product was determined by the FDA to be therapeutically equivalent to Adrenalin distributed in the U.S. by Par Pharmaceutical, Epinephrine Injection Multiple Dose Vial is for intramuscular, subcutaneous, and intravenous use, and is indicated for emergency treatment of allergic reactions, including anaphylaxis, and to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. Additionally, the FDA granted 180 day exclusivity to Amphastar as the first generic filer. Amphastar plans to launch this Epinephrine Injection Multiple Dose Vial within two to three months.

ShowHide Related Items >><<
AMPH Amphastar
$16.75 /

+0.23 (+1.39%)

01/22/20 Wells Fargo
Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo
07/10/19 Wells Fargo
Amneal news reflects challenges in generics industry, says Wells Fargo
06/06/19 Wells Fargo
Wells says filings indicate resolution of Amphastar dispute with Sandoz/Momenta
05/30/19 Wells Fargo
U.S. generic data continues to show challenging environment, says Wells Fargo
Over a quarter ago
Hot Stocks
Amphastar currently has seven ANDAs filed with the FDA » 16:31
03/12/20
03/12
16:31
03/12/20
16:31
AMPH

Amphastar

$13.94 /

-1.38 (-9.01%)

The Company currently has…

The Company currently has seven ANDAs filed with the FDA targeting products with a market size of approximately $1.9 billion, three biosimilar products in development targeting products with a market size of approximately $13 billion, and nine generic products in development targeting products with a market size of approximately $12 billion. This market information is based on IQVIA data for the 12 months ended December 31, 2019. The Company's proprietary pipeline includes a new drug application for intranasal naloxone. The Company is currently developing four other proprietary products, which include injectable and intranasal dosage forms.

ShowHide Related Items >><<
AMPH Amphastar
$13.94 /

-1.38 (-9.01%)

01/22/20 Wells Fargo
Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo
07/10/19 Wells Fargo
Amneal news reflects challenges in generics industry, says Wells Fargo
06/06/19 Wells Fargo
Wells says filings indicate resolution of Amphastar dispute with Sandoz/Momenta
05/30/19 Wells Fargo
U.S. generic data continues to show challenging environment, says Wells Fargo
Earnings
Amphastar reports Q4 EPS 7c, consensus 7c » 16:30
03/12/20
03/12
16:30
03/12/20
16:30
AMPH

Amphastar

$13.94 /

-1.38 (-9.01%)

Reports Q4 revenue…

Reports Q4 revenue $83.4M, consensus $81.79M. Dr. Jack Zhang, Amphastar's Chief Executive Officer, commented: "We finished 2019 with very strong sales of Primatene(R) Mist, with fourth quarter sales essentially equaling sales in the previous three quarters combined. Additionally, we have made great progress with our pipeline of product candidates, as we continue to move forward with clinical trials for both our insulin and inhalation products. In addition, the FDA accepted two more of our ANDAs."

ShowHide Related Items >><<
AMPH Amphastar
$13.94 /

-1.38 (-9.01%)

01/22/20 Wells Fargo
Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo
07/10/19 Wells Fargo
Amneal news reflects challenges in generics industry, says Wells Fargo
06/06/19 Wells Fargo
Wells says filings indicate resolution of Amphastar dispute with Sandoz/Momenta
05/30/19 Wells Fargo
U.S. generic data continues to show challenging environment, says Wells Fargo
Hot Stocks
Amphastar receives FDA approval of sNDA for Sodium Bicarbonate Injection » 06:09
02/27/20
02/27
06:09
02/27/20
06:09
AMPH

Amphastar

$17.28 /

-0.07 (-0.40%)

Amphastar announced that…

Amphastar announced that the U.S. FDA granted approval of its supplemental Abbreviated New Drug Application for Sodium Bicarbonate Injection, USP, 8.4%, 50mEq/50mL Single-Dose Prefilled Syringe. This supplement is for manufacturing the product in the company's new manufacturing line at its International Medication Systems facility.

ShowHide Related Items >><<
AMPH Amphastar
$17.28 /

-0.07 (-0.40%)

01/22/20 Wells Fargo
Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo
07/10/19 Wells Fargo
Amneal news reflects challenges in generics industry, says Wells Fargo
06/06/19 Wells Fargo
Wells says filings indicate resolution of Amphastar dispute with Sandoz/Momenta
05/30/19 Wells Fargo
U.S. generic data continues to show challenging environment, says Wells Fargo
Periodicals
Gilead, Astellas Pharma sue Amphastar over Lexiscan copies, Bloomberg reports » 08:06
02/26/20
02/26
08:06
02/26/20
08:06
GILD

Gilead

$70.13 /

-2.82 (-3.87%)

, ALPMY

Astellas Pharma

$0.00 /

+ (+0.00%)

, AMPH

Amphastar

$17.35 /

-0.24 (-1.36%)

Gilead (GILD) and…

Gilead (GILD) and Astellas Pharma (ALPMY) are seeking a court order to block copies of the Lexiscan drug by Amphastar's (AMPH) Internatinal Medication Systems unit, saying the Amphastar unit is infringing three patents, Bloomberg's Christopher Yasiejko reports. Gilead owns the patents and licenses for Lexiscan, which helps doctors detect coronary artery disease, and licenses them exclusively to Astellas, according to the report. Reference Link

ShowHide Related Items >><<
GILD Gilead
$70.13 /

-2.82 (-3.87%)

02/25/20 Stifel
Iovance among 'more interesting' cell therapy takeout candidates, says Stifel
02/24/20 SunTrust
SunTrust says Gilead's remdesivir unlikely to add to topline
02/24/20 BofA
BofA stays cautious on Gilead as remdesivir hope drives shares higher
02/24/20 Stifel
Galapagos price target raised to $298 from $188 at Stifel
ALPMY Astellas Pharma
$0.00 /

+ (+0.00%)

01/23/20 Morgan Stanley
Astellas Pharma resumed with an Overweight at Morgan Stanley
12/05/19 JPMorgan
Audentes Therapeutics downgraded to Neutral from Overweight at JPMorgan
12/03/19 Raymond James
Audentes downgraded to Market Perform from Outperform at Raymond James
12/03/19 H.C. Wainwright
Audentes Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
AMPH Amphastar
$17.35 /

-0.24 (-1.36%)

01/22/20 Wells Fargo
Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo
07/10/19 Wells Fargo
Amneal news reflects challenges in generics industry, says Wells Fargo
06/06/19 Wells Fargo
Wells says filings indicate resolution of Amphastar dispute with Sandoz/Momenta
05/30/19 Wells Fargo
U.S. generic data continues to show challenging environment, says Wells Fargo

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.